Xarelto: Ph III COMPASS data

Johnson & Johnson’s Janssen Research & Development LLC unit said the double-blind, placebo-controlled, international Phase III COMPASS trial evaluating oral Xarelto in 27,402 CAD or PAD patients was stopped early on the recommendation of an independent DMC after the trial met its primary endpoint of reducing MACE. The company declined to disclose additional data. Patients received twice-daily 2.5 mg Xarelto plus aspirin, twice-daily 5 mg Xarelto alone or aspirin alone. COMPASS is part of the EXPLORER clinical research program evaluating Xarelto in a target population of >275,000 patients. The program includes 10 indication-seeking and label expansion studies beyond the 6 indications for which the drug is approved in the U.S...